H5P Stock Overview
Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Hikma Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£22.60 |
| 52 Week High | UK£24.60 |
| 52 Week Low | UK£19.80 |
| Beta | 0.44 |
| 11 Month Change | -4.24% |
| 3 Month Change | -5.04% |
| 1 Year Change | 10.78% |
| 33 Year Change | -16.91% |
| 5 Year Change | 0.80% |
| Change since IPO | 455.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| H5P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.6% | -5.0% | -1.3% |
| 1Y | 10.8% | -22.0% | 7.4% |
Return vs Industry: H5P exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: H5P exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| H5P volatility | |
|---|---|
| H5P Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: H5P has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: H5P's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 9,100 | Riad Mishlawi | www.hikma.com |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Hikma Pharmaceuticals PLC Fundamentals Summary
| H5P fundamental statistics | |
|---|---|
| Market cap | €4.99b |
| Earnings (TTM) | €272.35m |
| Revenue (TTM) | €2.88b |
18.3x
P/E Ratio1.7x
P/S RatioIs H5P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H5P income statement (TTM) | |
|---|---|
| Revenue | US$3.02b |
| Cost of Revenue | US$1.57b |
| Gross Profit | US$1.45b |
| Other Expenses | US$1.16b |
| Earnings | US$285.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.29 |
| Gross Margin | 47.99% |
| Net Profit Margin | 9.45% |
| Debt/Equity Ratio | 53.2% |
How did H5P perform over the long term?
See historical performance and comparison